Misonix manufactured and marketed scientific and industrial ultrasonic products and was developing a number of minimally invasive ultrasonic medical devices for angioplasty, liposuction and other surgical procedures.
The Company sought to strengthen its resources to continue the development of its medical devices, including obtaining FDA approval and establishing manufacturing and marketing capabilities.
A principal of Carter Morse & Mathias acted as lead underwriter on Misonix’s IPO and subsequently served on the Board of Directors.
Securities are offered through Carter Capital Corporation, memberFINRA and SIPC.
This information should not be construed as a recommendation, offer to sell, or solicitation of an offer to buy a particular security or investment strategy. The commentary provided is for informational purposes only and should not be relied on for accounting, legal, tax or other professional advice. While the information herein is deemed reliable, CMM cannot guarantee its accuracy, completeness, or suitability for any purpose, and makes no warranties with regard to the results to be obtained from its use.